This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Toric Intraocular Lens Following Cataract Surgery

This study has been completed.
Information provided by (Responsible Party):
Bausch & Lomb Incorporated Identifier:
First received: June 8, 2010
Last updated: August 29, 2014
Last verified: August 2014
The objective of this clinical trial is to evaluate the safety and effectiveness of the Bausch + Lomb Toric Accommodating Posterior Chamber Silicone Intraocular Lens used to provide near, intermediate, and distance vision and a reduction of the effects of preoperative corneal astigmatism in presbyopic patients undergoing cataract extraction and intraocular lens (IOL) placement.

Condition Intervention
Cataract Astigmatism Device: Toric Accommodating Lens Device: Accommodating Lens

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Prospective Multicenter Clinical Trial To Evaluate the Effectiveness of A Toric Accommodating Posterior Chamber Silicone Intraocular Lens Designed To Provide Near, Intermediate, And Distance Vision And Reduce The Effects Of Preoperative Corneal Astigmatism On Postoperative Refraction Following Cataract Surgery

Resource links provided by NLM:

Further study details as provided by Bausch & Lomb Incorporated:

Primary Outcome Measures:
  • Percent Reduction in Absolute Cylinder [ Time Frame: 120 - 180 day postoperative visit ]
    Percent reduction in absolute cylinder expressed as a percentage of the intended reduction in cylinder. Cylinder reduction is the measurement for astigmatism reduction. Astigmatism is a form of refractive error that can affect uncorrected visual acuity (at all distances). Reducing cylinder should improve UCVA, but other elements of refractive error, such as myopia or hyperopia, can also affect UCVA. Best corrected visual acuity (BCVA) is not affected by refractive error.

Secondary Outcome Measures:
  • Lens Misalignment [ Time Frame: 120 - 180 day postoperative visit ]
    This Outcome Measure was evaluated for Crystalens Toric IOL arm only - Toric IOLs require precise alignment to correct astigmatism; control IOLs do not.

  • Visual Acuity [ Time Frame: 120 - 180 day postoperative visit ]
    Best-Corrected Distance Visual Acuity (BCDVA) without Glare (logMAR)

Enrollment: 229
Study Start Date: June 2010
Study Completion Date: October 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Crystalens toric IOL
Toric Accommodating Lens Crystalens toric silicone multi-piece accommodating IOL (Models AT-50T/AT-52T)
Device: Toric Accommodating Lens
Toric accommodating lens implanted after cataract extraction
Active Comparator: Crystalens IOL
Accommodating Lens Crystalens silicone multi-piece accommodating IOL (Models AT-50SE/AT-52SE)
Device: Accommodating Lens
Accommodating lens implanted after cataract extraction


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have a clinically documented diagnosis of age-related cataract
  • Subjects must require a lens power from 16 to 27 diopters
  • Subjects must have predicted post-operative corneal astigmatism between 0.83D and 2.50D, as determined by the Toric Calculator

Exclusion Criteria:

  • Subjects with any anterior segment pathology for which extracapsular/ phacoemulsification cataract surgery would be contraindicated.
  • Subjects with diagnoses of degenerative visual disorders.
  • Subjects with conditions associated with increased risk of zonular rupture.
  • Subjects who have had previous corneal surgery in the planned operative eye.
  • Subjects with irregular corneal astigmatism.
  • Subjects with clinically significant retinal pigment or epithelium/macular changes.
  • Subjects with chronic use of systemic steroids or immunosuppressive medications.
  • Subjects either concurrently participating in another clinical trial or have participated in another clinical trial within 60 days prior to enrollment in this study.
  • Subjects with a difference in corneal astigmatism measured with the IOL Master and the topographer greater than 0.5 D using vector analysis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01140477

United States, New Jersey
B&L Surgical
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Bausch & Lomb Incorporated
Study Director: Jay Pepose, MD, PhD Pepose Vision Institute
  More Information

Responsible Party: Bausch & Lomb Incorporated Identifier: NCT01140477     History of Changes
Other Study ID Numbers: 650
Study First Received: June 8, 2010
Results First Received: August 7, 2014
Last Updated: August 29, 2014

Additional relevant MeSH terms:
Lens Diseases
Eye Diseases
Refractive Errors processed this record on September 21, 2017